首页> 美国卫生研究院文献>Neoplasia (New York N.Y.) >Glucosamine-Bound Near-Infrared Fluorescent Probes with Lysosomal Specificity for Breast Tumor Imaging
【2h】

Glucosamine-Bound Near-Infrared Fluorescent Probes with Lysosomal Specificity for Breast Tumor Imaging

机译:具有溶酶体特异性的葡萄糖胺结合的近红外荧光探针用于乳腺肿瘤成像

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Noninvasive imaging of lysosomes will be useful 1) to elucidate the role of lysosomal parameters in cancer, 2) to diagnose malignant lesions, and 3) to evaluate future lysosome-targeted anticancer therapies. Lysosome-specific labeling of glucosamine-bound near-infrared (NIR) fluorescent probes, IR-1 and IR-2, but not control probe IR-15 without the glucosamine moiety, was observed by fluorescence microscopy in human breast epithelial cell lines. Lysosome labeling and tumor specificity of these NIR probes were investigated by dynamic optical imaging and immunofluorescence staining in human breast tumor xenografts. IR-1 and IR-2 demonstrated faster lysosome labeling rates in highly aggressive MDA-MB-231 and MDA-MB-435 cells compared with less aggressive MCF-7 and nontumorigenic MCF-12A cells. IR-1 and IR-2, but not IR-15, accumulated in human MDA-MB-231, MDA-MB-435, and MCF-7 breast tumor xenografts in vivo. IR-2 demonstrated the highest maximum fluorescence and tumorormal tissue ratios in all tumor models. Specific lysosome labeling from IR-2 in vivo was validated by colocalization of the NIR fluorescence with CD63 immunofluorescence in tumor sections. IR-1 and IR-2 demonstrated high lysosome-labeling ability and breast tumor-targeting specificity in vitro and in vivo. They are promising for diagnosing malignant lesions and may provide a means for evaluating and monitoring future lysosome-targeted anticancer therapies.
机译:溶酶体的非侵入性成像将非常有用:1)阐明溶酶体参数在癌症中的作用; 2)诊断恶性病变; 3)评估未来针对溶酶体的抗癌疗法。通过荧光显微镜在人乳腺上皮细胞系中观察到葡糖胺结合的近红外(NIR)荧光探针IR-1和IR-2的溶酶体特异性标记,但没有不含葡糖胺部分的对照探针IR-15。这些NIR探针的溶酶体标记和肿瘤特异性通过动态光学成像和免疫荧光染色在人乳腺肿瘤异种移植物中进行了研究。 IR-1和IR-2与高侵袭性MCF-7和非致瘤MCF-12A细胞相比,在高侵略性MDA-MB-231和MDA-MB-435细胞中显示出更快的溶酶体标记率。 IR-1和IR-2而非IR-15在体内的人MDA-MB-231,MDA-MB-435和MCF-7乳腺异种移植物中积累。 IR-2在所有肿瘤模型中均显示出最高的最大荧光和肿瘤/正常组织比率。通过在肿瘤切片中将NIR荧光与CD63免疫荧光共定位来验证IR-2在体内的特异性溶酶体标记。 IR-1和IR-2在体外和体内均显示出较高的溶酶体标记能力和靶向乳腺肿瘤的特异性。它们有望用于诊断恶性病变,并可能提供一种评估和监测以溶酶体为靶点的抗癌疗法的手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号